JP4761389B2 - 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 - Google Patents

染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 Download PDF

Info

Publication number
JP4761389B2
JP4761389B2 JP2006512126A JP2006512126A JP4761389B2 JP 4761389 B2 JP4761389 B2 JP 4761389B2 JP 2006512126 A JP2006512126 A JP 2006512126A JP 2006512126 A JP2006512126 A JP 2006512126A JP 4761389 B2 JP4761389 B2 JP 4761389B2
Authority
JP
Japan
Prior art keywords
protein
gene
dna
cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006512126A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2005097189A1 (ja
Inventor
基樹 高木
和伸 二見
顕 嶋本
泰宏 古市
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genecare Research Institute Co Ltd
Original Assignee
Genecare Research Institute Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genecare Research Institute Co Ltd filed Critical Genecare Research Institute Co Ltd
Priority to JP2006512126A priority Critical patent/JP4761389B2/ja
Publication of JPWO2005097189A1 publication Critical patent/JPWO2005097189A1/ja
Application granted granted Critical
Publication of JP4761389B2 publication Critical patent/JP4761389B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
JP2006512126A 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 Expired - Fee Related JP4761389B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006512126A JP4761389B2 (ja) 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004115404 2004-04-09
JP2004115404 2004-04-09
JP2006512126A JP4761389B2 (ja) 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
PCT/JP2005/006914 WO2005097189A1 (ja) 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011026980A Division JP5213972B2 (ja) 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Publications (2)

Publication Number Publication Date
JPWO2005097189A1 JPWO2005097189A1 (ja) 2008-02-28
JP4761389B2 true JP4761389B2 (ja) 2011-08-31

Family

ID=35124844

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006512126A Expired - Fee Related JP4761389B2 (ja) 2004-04-09 2005-04-08 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
JP2011026980A Expired - Fee Related JP5213972B2 (ja) 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
JP2012046652A Expired - Fee Related JP5390653B2 (ja) 2004-04-09 2012-03-02 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011026980A Expired - Fee Related JP5213972B2 (ja) 2004-04-09 2011-02-10 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
JP2012046652A Expired - Fee Related JP5390653B2 (ja) 2004-04-09 2012-03-02 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤

Country Status (5)

Country Link
US (3) US8193332B2 (https=)
EP (4) EP2520652B1 (https=)
JP (3) JP4761389B2 (https=)
KR (1) KR101234281B1 (https=)
WO (1) WO2005097189A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1625853B1 (en) 2003-05-19 2015-07-08 Genecare Research Institute Co., Ltd Apoptosis inducer for cancer cell
EP2520652B1 (en) 2004-04-09 2015-06-10 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
EP1816194A4 (en) * 2004-11-19 2009-02-18 Genecare Res Inst Co Ltd CANCER-SPECIFIC PROLIFERATION INHIBITORS
US20090208938A1 (en) * 2005-02-10 2009-08-20 Centre National De La Recherche Scientifique Use of the MCM8 Gene for the Preparation of a Pharmaceutical Composition
EP1915622A2 (en) * 2005-07-29 2008-04-30 Oncotherapy Science, Inc. Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex
GB0606096D0 (en) 2006-03-27 2006-05-03 Cbmm Sa Screening method
WO2008047574A1 (fr) * 2006-09-28 2008-04-24 Genecare Research Institute Co., Ltd. Sensibilisateur pour agent anticancéreux
JP4940412B2 (ja) * 2006-10-16 2012-05-30 財団法人ヒューマンサイエンス振興財団 抗癌性物質のスクリーニング方法
CA2666584A1 (en) * 2006-10-17 2008-04-24 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
WO2010034487A2 (en) * 2008-09-23 2010-04-01 Silence Therapeutics Ag Means for inhibiting the expression of orc-1
WO2010045526A1 (en) * 2008-10-17 2010-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Geminin inhibitors as tumor treatment
EP2370580B1 (en) * 2008-12-04 2019-09-11 CuRNA, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
EP2403946A4 (en) * 2009-03-04 2012-11-14 TREATMENT OF SIRTUIN 1 (SIRT1) -HANDLED ILLNESSES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST SIRT 1
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
US8435961B2 (en) * 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
US20110097329A1 (en) 2009-06-26 2011-04-28 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
EP2467481A4 (en) * 2009-07-24 2013-01-16 Curna Inc TREATMENT OF SIRTUIN (SIRT) -REVATED ILLNESSES BY INHIBITING THE NATURAL ANTISENSE TRANSCRIPT AGAINST A SIRTUIN (SIRT)
NZ602089A (en) 2010-02-17 2014-05-30 Takeda Pharmaceutical Heterocyclic compounds having cell division cycle 7 inhibitory activity
US20130071395A1 (en) * 2010-05-28 2013-03-21 Case Western Reserve University Compositions and methods for treating pathologies
WO2012090479A1 (en) * 2010-12-28 2012-07-05 Oncotherapy Science, Inc. Mcm7 as a target gene for cancer therapy and diagnosis
US20150087687A1 (en) 2012-03-23 2015-03-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
US9512486B2 (en) * 2012-08-06 2016-12-06 The Institute Of Cancer Research: Royal Cancer Hospital Materials, methods, and systems for treating cancer
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
KR101623814B1 (ko) 2014-02-21 2016-05-24 두산중공업 주식회사 수냉각 발전기의 분리형 냉각수 순환 구조 및 그에 따른 냉각 방법
JP2015167527A (ja) * 2014-03-07 2015-09-28 学校法人東京理科大学 標的タンパク質の量の低減のためのポリペプチド、単離された核酸、組み換えベクター、及び形質転換体
EP3237444B1 (en) * 2014-12-23 2020-05-06 Centre National De La Recherche Scientifique Use of rad18 inhibitors in the treatment of tumors
CN104673801B (zh) * 2015-02-12 2018-09-11 中山大学附属第三医院 一种肝癌基因ndc80及其应用
CN107771285A (zh) 2015-06-08 2018-03-06 阿奎尔诊断有限公司 方法
EP4060344A1 (en) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
AU2017327384B2 (en) * 2016-09-13 2021-05-20 The Jackson Laboratory Targeted enhanced DNA demethylation
EP3533869B1 (en) * 2016-10-26 2025-08-20 Denka Company Limited Mutant human dna polymerase
US20200121703A1 (en) * 2017-06-26 2020-04-23 The Cleveland Clinic Foundation Cancer treatment
WO2020055187A1 (ko) * 2018-09-12 2020-03-19 기초과학연구원 유전자가 변이된 세포의 사멸 유도 조성물 및 상기 조성물을 이용한 유전자가 변형된 세포 사멸 유도 방법
JP2022020872A (ja) * 2020-06-01 2022-02-02 均 石井 抗がん剤。

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074654A2 (en) * 2002-02-20 2003-09-12 Sirna Therapeurics, Inc Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2004033666A2 (en) * 2002-10-11 2004-04-22 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3386597A (en) * 1996-06-11 1998-01-07 Advanced Research And Technology Institute, Inc. Methods and compositions for the use of apurinic/apyrimidinic endonucleases
GB0004193D0 (en) * 2000-02-22 2000-04-12 Isis Innovation A genetic determinant for malignant melanoma
US6773883B2 (en) * 2000-07-31 2004-08-10 The Brigham & Women's Hospital, Inc. Prognostic classification of endometrial cancer
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US7241743B2 (en) 2001-06-15 2007-07-10 The Trustees Of Columbia University In The City Of New York Sir2α-based therapeutic and prophylactic methods
WO2003046207A2 (en) 2001-11-27 2003-06-05 Fred Hutchinson Cancer Research Center Methods for inhibiting deacetylase activity
AU2003250831A1 (en) * 2002-06-12 2003-12-31 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of hec1 antagonists in the treatment of proliferative disorders and cancer
EP2305812A3 (en) * 2002-11-14 2012-06-06 Dharmacon, Inc. Fuctional and hyperfunctional sirna
EP1620573A4 (en) * 2003-04-15 2006-12-20 Avalon Pharmaceuticals DETERMINATION OF CANCER-ASSOCIATED GENES AND THERAPEUTIC OBJECTS USING MOLECULAR CYTOGENETIC PROCEDURES
WO2004094636A1 (en) 2003-04-24 2004-11-04 Galapagos Genomics N.V. Effective sirna knock-down constructs
EP1625853B1 (en) 2003-05-19 2015-07-08 Genecare Research Institute Co., Ltd Apoptosis inducer for cancer cell
EP2520652B1 (en) 2004-04-09 2015-06-10 Genecare Research Institute Co., Ltd Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associates genes
EP1816194A4 (en) 2004-11-19 2009-02-18 Genecare Res Inst Co Ltd CANCER-SPECIFIC PROLIFERATION INHIBITORS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003074654A2 (en) * 2002-02-20 2003-09-12 Sirna Therapeurics, Inc Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2004033666A2 (en) * 2002-10-11 2004-04-22 Board Of Regents, The University Of Texas System Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases

Also Published As

Publication number Publication date
JP2011168588A (ja) 2011-09-01
EP2495324A3 (en) 2012-10-17
US20090028861A1 (en) 2009-01-29
US8703930B2 (en) 2014-04-22
EP2495324A2 (en) 2012-09-05
US20120225928A1 (en) 2012-09-06
WO2005097189A1 (ja) 2005-10-20
EP2520652B1 (en) 2015-06-10
EP2520652A3 (en) 2012-12-05
EP2495324B1 (en) 2015-03-04
EP1757306A4 (en) 2010-05-19
US8193332B2 (en) 2012-06-05
JPWO2005097189A1 (ja) 2008-02-28
EP2481802A3 (en) 2012-10-17
US20130245097A1 (en) 2013-09-19
EP2481802A2 (en) 2012-08-01
EP2520652A2 (en) 2012-11-07
KR101234281B1 (ko) 2013-02-18
JP5213972B2 (ja) 2013-06-19
JP5390653B2 (ja) 2014-01-15
JP2012131818A (ja) 2012-07-12
EP2481802B1 (en) 2015-06-10
KR20060135945A (ko) 2006-12-29
EP1757306A1 (en) 2007-02-28
US8470798B2 (en) 2013-06-25

Similar Documents

Publication Publication Date Title
JP5390653B2 (ja) 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
Demin et al. XRCC1 prevents toxic PARP1 trapping during DNA base excision repair
Wang et al. Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors
Salguero et al. MDC1 PST-repeat region promotes histone H2AX-independent chromatin association and DNA damage tolerance
Engelward et al. A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in the mammalian genome
Kollárovič et al. The human HELLS chromatin remodelling protein promotes end resection to facilitate homologous recombination and contributes to DSB repair within heterochromatin
Zhao et al. A critical role for the ubiquitin-conjugating enzyme Ubc13 in initiating homologous recombination
Gottipati et al. Poly (ADP-Ribose) polymerase is hyperactivated in homologous recombination–defective cells
Lin et al. Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis
Reynolds et al. Rapid DNA double-strand breaks resulting from processing of Cr-DNA cross-links by both MutS dimers
Wiebusch et al. p53-and p21-dependent premature APC/C–Cdh1 activation in G2 is part of the long-term response to genotoxic stress
Chiang et al. Mitochondrial protein-linked DNA breaks perturb mitochondrial gene transcription and trigger free radical–induced DNA damage
Abolhassani et al. NUDT16 and ITPA play a dual protective role in maintaining chromosome stability and cell growth by eliminating dIDP/IDP and dITP/ITP from nucleotide pools in mammals
Futami et al. RECQL1 and WRN DNA repair helicases: potential therapeutic targets and proliferative markers against cancers
Gromyko et al. Depletion of the human Nα‐terminal acetyltransferase A induces p53‐dependent apoptosis and p53‐independent growth inhibition
Kaushik Tiwari et al. XPD-dependent activation of apoptosis in response to triplex-induced DNA damage
Balajee Human RecQL4 as a novel molecular target for cancer therapy
Hertz et al. The SUMO–NIP45 pathway processes toxic DNA catenanes to prevent mitotic failure
Lim et al. Activation of AMP-activated protein kinase by MAPO1 and FLCN induces apoptosis triggered by alkylated base mismatch in DNA
US20090149377A1 (en) METHODS FOR REGULATION OF p53 TRANSLATION AND FUNCTION
Kulkarni et al. XRCC1 protects against the lethality of induced oxidative DNA damage in nondividing neural cells
Song et al. Unpredicted downregulation of RAD51 suggests genome instability induced by tetrachlorobenzoquinone
Said Interplay between Senataxin and FANCD2 in genome maintenance
Khan et al. RAD51 and RAD51 paralog inhibition sensitizes nonreplicating quiescent keratinocytes to UV radiation
Zagnoli Vieira Investigating the effect of TDP2 absence in CRISPR/Cas9 knock-out or patient-derived cell lines

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110309

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110601

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110602

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140617

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees